Teva Pharmaceutical agrees to purchase W.R. Grace's 49.8% stake in the joint venture for $20 mil. As a result, Teva will own 100% of the Lemmon generics business. After the deal, which is expected to close within 90 days, W.R. Grace will continue to hold a 14% equity position in Teva.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.